Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.
Saved in:
| Title: | Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. |
|---|---|
| Authors: | Autio KA; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Antonarakis ES; University of Minnesota Medical School, Minneapolis, MN, USA., Mayer TM; Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA., Shevrin DH; NorthShore University HealthSystem, Evanston, IL, USA., Stein MN; Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY, USA., Vaishampayan UN; University of Michigan, Ann Arbor, MI, USA., Morris MJ; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Slovin SF; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Heath EI; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA., Tagawa ST; Weill Cornell Medical College, New York, NY, USA., Rathkopf DE; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA., Milowsky MI; UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA., Harrison MR; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA., Beer TM; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Balar AV; New York University, New York, NY, USA., Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA., George DJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC, USA., Paller CJ; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, Baltimore, MD, USA., Apollo A; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Danila DC; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Graff JN; Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA., Nordquist L; Urology Cancer Center and GU Research Network, Omaha, NE, USA., Dayan Cohn ES; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Tse K; Columbia University, New York, NY, USA., Schreiber NA; Convergent Therapeutics, New York, NY, USA., Heller G; Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Scher HI; Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.; Weill Cornell Medical College, New York, NY, USA.; Prostate Cancer Clinical Trials Consortium, New York, NY, USA. |
| Source: | European urology open science [Eur Urol Open Sci] 2021 Nov 17; Vol. 34, pp. 70-78. Date of Electronic Publication: 2021 Nov 17 (Print Publication: 2021). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101771568 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-1683 (Electronic) Linking ISSN: 26661683 NLM ISO Abbreviation: Eur Urol Open Sci Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
